VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Histologically confirmed PD-L1 status defined      │ Histologically confirmed PD-L1 status defined      │     100 │
│ NSCLC. Biopsy must be within 70 days of first      │ NSCLC. Biopsy must be within 70 days of first      │         │
│ treatment with pembrolizumab                       │ treatment with pembrolizumab                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ECOG performance status 2                          │ ECOG performance status 2                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uni-dimensionally measurable disease according to  │ Uni-dimensionally measurable disease according to  │     100 │
│ Response Evaluation Criteria in Solid Tumours      │ Response Evaluation Criteria in Solid Tumours      │         │
│ (RECIST) v1.1                                      │ (RECIST) v1.1                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Computerised Tomography (CT) scan of chest and     │ Computerised Tomography (CT) scan of chest and     │     100 │
│ abdomen within 28 days of starting pembrolizumab   │ abdomen within 28 days of starting pembrolizumab   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adequate haematological function                   │ Adequate haematological function                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count ≥100 x 109 /L                       │ Platelet count ≥100 x 109 /L                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Neutrophils ≥1.5 x 109/L                           │ Neutrophils ≥1.5 x 109/L                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adequate hepatic function                          │ Adequate hepatic function                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum bilirubin ≤1.5 x upper limit of normal (ULN) │ Serum bilirubin ≤1.5 x upper limit of normal (ULN) │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum transaminases ≤2.5 x ULN                     │ Serum transaminases ≤2.5 x ULN                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Untreated symptomatic brain or leptomeningeal      │ Untreated symptomatic brain or leptomeningeal      │     100 │
│ metastatic disease                                 │ metastatic disease                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any medical condition which in the opinion of the  │ Any medical condition which in the opinion of the  │     100 │
│ investigator would compromise the ability of the   │ investigator would compromise the ability of the   │         │
│ patient to participate in the trial or which would │ patient to participate in the trial or which would │         │
│ jeopardise compliance with the protocol            │ jeopardise compliance with the protocol            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active autoimmune disease that has required        │ Active autoimmune disease that has required        │     100 │
│ systemic treatment in past 2 years                 │ systemic treatment in past 2 years                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic usage of steroids or other                 │ Chronic usage of steroids or other                 │     100 │
│ immunosuppressant medication                       │ immunosuppressant medication                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous history of pneumonitis                    │ Previous history of pneumonitis                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any evidence of clinical autoimmunity              │ Any evidence of clinical autoimmunity              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Haemoglobin ≥ 90 g/L                               │ Haemoglobin ≥ 9g/dL                                │      92 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Provision of signed and dated, written informed    │ Provision of signed and dated, written informed    │      97 │
│ consent prior to any trial specific procedures,    │ consent prior to any study specific procedures,    │         │
│ sampling and analyses                              │ sampling and analyses                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy \> 12 weeks                        │ Life expectancy > 12 weeks                         │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medical or psychiatric conditions compromising     │ Medical or psychiatric conditions comprising       │      98 │
│ informed consent                                   │ informed consent                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adequate renal function: Creatinine clearance      │ Adequate renal function: Creatinine clearance <1.5 │      99 │
│ \<1.5 times ULN concurrent with creatinine         │ times ULN concurrent with creatinine clearance >50 │         │
│ clearance \>50 ml/min                              │ ml/min                                             │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════╤═════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                              │ CHIA Criteria                                   │   Score │
╞════════════════════════════════════════════════╪═════════════════════════════════════════════════╪═════════╡
│ Core                                           │ ECOG performance status 2                       │      28 │
├────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years              │ Radiotherapy within 4 weeks of trial entry      │      40 │
├────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Patients who do not meet the criteria of       │ Provision of signed and dated, written informed │      42 │
│ performance status = 2 on the ECOG Performance │ consent prior to any study specific procedures, │         │
│ scale                                          │ sampling and analyses                           │         │
├────────────────────────────────────────────────┼─────────────────────────────────────────────────┼─────────┤
│ Radiotherapy within 28 days of trial treatment │ Radiotherapy within 4 weeks of trial entry      │      80 │
╘════════════════════════════════════════════════╧═════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════╤════════════════════════════════════════════╤═════════╕
│ Personal Criteria                              │ CHIA Criteria                              │   Score │
╞════════════════════════════════════════════════╪════════════════════════════════════════════╪═════════╡
│ Radiotherapy within 28 days of trial treatment │ Radiotherapy within 4 weeks of trial entry │      80 │
╘════════════════════════════════════════════════╧════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 94
Average Levenshtein Ratio of individual lines: 90.53846153846153
OverAll Ratio: 92.26923076923077
